Gut Microbiome Analysis in Organ Transplant Recipient - Trial NCT06405958
Access comprehensive clinical trial information for NCT06405958 through Pure Global AI's free database. This phase not specified trial is sponsored by Asan Medical Center and is currently Not yet recruiting. The study focuses on Microbial Colonization. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Asan Medical Center
Timeline & Enrollment
N/A
May 01, 2024
Dec 31, 2026
Primary Outcome
Changes in the gut Microbiome
Summary
The microbiome acts as an antigen and can induce signaling through receptors like TLRs and
 NODs. Microbial metabolites can directly act on gut cells or reach other organs systemically.
 Studies show that the commensal, non-pathogenic microbiota plays an important role in
 regulating the immune system in various ways:
 
 - Promoting differentiation of Th17 cells and ILC3 signaling to regulate IL-17A production
 
 - Influencing iNKT cell generation early in life to prevent inflammatory activities
 
 - Facilitating CD4+ T cell differentiation and balancing Th1/Th2 responses
 
 - Inducing regulatory T cells (Tregs) that promote immune homeostasis
 
 - Tregs in Peyer's patches help maintain a microbiome that supports homeostasis
 
 The microbiome influences T cells, B cells and immune homeostasis. This has implications for
 transplantation, where modulating the microbiome could impact the graft's acceptance by
 affecting the recipient's immune cells that respond to the transplant.
 
 In summary, it highlights the microbiome's role in immune regulation and the potential for
 leveraging this interaction therapeutically, including in the context of transplantation.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06405958
Non-Device Trial